Log In | Shopping Cart | Advanced Search
            
  • Home
  • Career
  • Distributors
  • Contact Us:
  • Email: crm@excellgen.com
Products
Modified mRNA
Encapsulated mRNA
mRNA Enzyme
SARS-CoV-2
Pseudovirus
Popular Products
Cancer Proteins
Antibodies
DNA Binding Proteins
Electrophoresis
Genome Engineering
Polymerases
Recombinases
Transcription Factors
Transfection
Comsumbles
Services
Modified mRNA
Custom Cloning
Virus Production
Protein Purification
Protein Expression
Antibodies
 Previous 
 Return to List 
 Next 

Anti-IL-13RA2 monoclonal antibody, recombinant

Catalog #: EG-373


$250.00

Qty:

EG-373 Anti-IL13Ra2-M2
Product Name Anti-IL-13RA2 monoclonal antibody, recombinant
Cat # EG-373
Size 100 µg
Key features Rabbit monoclonal antibody produced in 293 cells with serum-free, protein-free medium, purified with protein A column;
High batch-to-batch consistency and reproducibility;
Long term security of supply;
Clone number M2
Immunogen Recombinant extracellular domain of interleukin 13 receptor alpha 2 (IL-13RA2) that was expressed and purified from 293 cells
Reaction target Extracellular region of IL-13RA2
Species Cross-Reactivity Human
Applications Flow Cytometry; IP; ELISA;
Working concentrations Flow cytometry and ELISA: 5 µg/ml of final concentration is suggested.
IP: 10 μg in 0.3-0.5 mg cell lysates is suggested.
Background The interleukin-13 receptor alpha 2 (IL-13RA2) is a high-affinity membrane receptor for interleukin-13 (IL-13). IL-13 is a T helper 2(Th2)cell-derived pleiotropic immune regulatory cytokine that binds available IL-13RA2 with 50-fold higher affinity than the ubiquitously expressed receptor named interleukin-13 receptor alpha 1 (IL-13RA1) [1]. Under normal physiological conditions, IL-13 binds to the low-affinity receptor IL-13RA1 monomer and further forms a heterodimeric complex with IL-4RA, which subsequently triggers Janus kinase and signal transducer activation and activator of transcription (STAT). However, in cancer cells, IL-13 can bind IL-13Rα2 with high affinity in an IL-4-independent manner. IL-13RA2 is over-expressed in a vast majority of human patients with high-grade astrocytomas like glioblastoma, but not in normal brain tissues. Therefore, IL-13RA2 is a potential target for immunotherapy of glioblastoma, which is one of the most lethal brain tumors and there are no curative treatment modalities for this type of cancer. IL-13 fused pseudomonas exotoxin has been evaluated for its anti-tumor efficacy in clinical trials by targeting IL-13RA2, but failed due to side effect.
References: (1) Arima, K., et al., Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem, 2005; 280: 24915-22.
QC

ELISA assay showing protein binding affinity of the monoclonal antibody. The calculated EC50 value was 0.05 nM.

Concentration As indicated on the vials
Formulation 80% PBS, pH 7.4; 20% Glycerol; 5% Trehalose; 0.04% Sodium azide as Preservative
Shipping Blue ice
Storage -20 to -70 oC (long term) or 4 oC (one week).
Depending on the expected application frequency, the product can be aliquoted to avoid heavily repeated freezing/thawing cycles.

     
 Ask a Question 
 
 Home | Privacy Policy | Terms & Conditions | Online Price Policy | Shipping & Return

Copyright © 2007-2023  Excellgen, Inc. All rights reserved